Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Recent advance on genome editing for therapy of β-hemoglobinopathies.

Yi chuan = Hereditas - 20 Feb 2018

Liu Jia-Wei, Hong Tao, Qin Xin, Liang Ying-Min, Zhang Ping

Abstract excerpt

β-hemoglobinopathies are one of six groups of common illnesses affecting human health. Although the genetic mechanisms have been elucidated for several decades, curable treatment options, other than allogeneic bone marrow transplantation, are still lacking. In recent years, rapid development in genome editing technologies and their clinical applications have opened up new directions for treatment of...

Topics

CRISPR-Cas Systems
Fetal Hemoglobin
Gene Editing
Genetic Therapy
Hemoglobinopathies
Humans
Mutation
Translational Research, Biomedical
beta-Globins

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 29428902
DOI: 10.16288/j.yczz.17-215

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent advance on genome editing for therapy of β-hemoglobinopathies.PMID 29428902Read ↗

Genome Editing for β-Hemoglobinopathies: Advances and ChallengesSemantic proximity Read ↗

Customizing the genome as therapy for the β-hemoglobinopathiesSemantic proximity Read ↗

A Small Key for a Heavy Door: Genetic Therapies for the Treatment of HemoglobinopathiesSemantic proximity Read ↗

Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy.Semantic proximity Read ↗

Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathiesSemantic proximity Read ↗

Genome editing strategies for targeted correction of β-globin mutation in sickle cell disease: From bench to bedside.Semantic proximity Read ↗

Genome Editing for the β-Hemoglobinopathies.Semantic proximity Read ↗

Gene Therapy for HemoglobinopathiesSemantic proximity Read ↗

Recent advancements in gene therapy for sickle cell disease and β-thalassemiaSemantic proximity Read ↗

Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of β-hemoglobinopathiesSemantic proximity Read ↗

A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.Semantic proximity Read ↗

Clinical genome editing to treat sickle cell disease—A brief updateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.